Browse published site content mentioning or authored by this company. Sorted by original publication date; undated items appear last.
← Back to company profileShowing 1–8 / 8 related items
mRNA, RNP, plasmid, and viral vectors each make different biological and regulatory tradeoffs for Cas9 delivery. This comparison maps which format fits which program context, from ex vivo cell therapy to in vivo LNP editing.
FDA and EMA do not define a universal dsRNA threshold for RNA therapeutics. Learn what validated methods, stage-gated specifications, and comparability requirements are expected at each development stage in 2026.
A technical comparison of DNA and RNA gene therapy delivery systems, covering viral vectors, lipid nanoparticles, and non-viral platforms.
Antibodies, aptamers, and peptides as LNP targeting ligands: affinity, immune profile, and how to choose the best for your LNP formulation.
The best Cas9 mRNA for gene editing is defined by transcript integrity, dsRNA content, capping efficiency, nucleotide modification strategy, and functional validation in a cell-based potency assay. This guide explains what how to evaluate batch data, for researchers working proof of concept to early IND-enabling studies.
Double-stranded RNA (dsRNA) is an intrinsic IVT impurity that activates immune response and must be controlled in RNA therapeutics.
Understand RNA therapeutics, key RNA types, delivery technologies, and manufacturing (CMC) constraints that determine project feasibility
Lipid nanoparticles enable RNA delivery through controlled uptake and limited endosomal escape. Experimental outcomes depend on formulation and biology.
Name matches are discovery leads; verify entity identity and transaction roles in the original source. Same-field reading is kept separate.